Coeptis Therapeutics shifts focus with rebrand and AI tech

WEXFORD, Pa. - Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP), known for its work in cell therapy for various diseases, has announced a significant rebranding to COEPTIS, signaling a strategic shift to encompass technology and artificial intelligence (AI) alongside its biopharmaceutical endeavors. The company’s stock has shown remarkable momentum, delivering a 151.83% return over the past six months, according to InvestingPro data. The rebranding includes the creation of a new Technology Division and the recent acquisition of NexGenAI Affiliates Network platform, an AI-powered marketing solution.

The company’s move aims to leverage technology to enhance operational capabilities and increase shareholder value. With a current market capitalization of $25.47 million and an overall Financial Health score of FAIR from InvestingPro, COEPTIS is pursuing this transformation while managing moderate debt levels. By incorporating NexGenAI’s tools, COEPTIS plans to address marketing challenges with AI precision and efficiency and develop AI agents to optimize workflows through intelligent automation.

Dave Mehalick, President and CEO of Coeptis, emphasized that the strategic shift is designed to reinforce innovation and support the expansion into revenue-generating, cash flow-positive business units. He highlighted that NexGenAI offers practical AI solutions that stand out from traditional AI applications, focusing on enhancing communication strategies and sustainable growth.

Coeptis’s therapeutic portfolio includes assets licensed from Deverra Therapeutics, such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology. The company also collaborates with the University of Pittsburgh and other institutions on various cell therapy and diagnostic platforms.

The establishment of the Technology Division is an extension of Coeptis’s commitment to innovation, featuring AI-powered marketing software and robotic process automation tools designed to improve business efficiency. This division is a testament to the company’s strategy to grow beyond its core biopharmaceutical market.

The information in this article is based on a press release statement from Coeptis Therapeutics Holdings, Inc. According to InvestingPro, the company’s stock currently trades with high volatility and shows significant independence from broader market movements, with a beta of -1.04. InvestingPro subscribers have access to 12 additional investment tips and comprehensive financial metrics for COEP.

In other recent news, Coeptis Therapeutics secured a $1.1 million convertible note from YA II PN, LTD and raised approximately $10 million from its Series A Preferred Stock issuance. The biopharmaceutical company also reported securing $1.7 million from five new clients for its NexGenAI Affiliates Network platform, marking the initial success of the company’s AI-driven marketing solutions in the biopharma industry. Coeptis also announced a 1-for-20 reverse stock split, aiming to meet the Nasdaq Capital Market’s minimum bid price requirement.

Moreover, the company launched a new division, Coeptis Technologies, targeting the data security sector and expanded its license agreement with Deverra Therapeutics for the use of unmodified natural killer cells for pandemic preparedness and emergency use. Despite facing financial challenges and retracting its financial statements for several periods in 2023 and 2024 due to accounting errors, Coeptis appointed Astra Audit & Advisory, LLC as its new independent registered public accounting firm. Lastly, Coeptis secured an extension to remain listed on the Nasdaq until January 15, 2025, contingent on compliance with the minimum bid price requirement. These are the recent developments about Coeptis Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.